The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs

• Published in: Pharmacology research & perspectives Vol. 9; no. 3; pp. e00775 - n/a
• Main Authors: Trenaman, Shanna C., Bowles, Susan K., Andrew, Melissa K., Goralski, Kerry
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2021; John Wiley and Sons Inc; Wiley
• Subjects: Age; aging; Aging - genetics; Aging - metabolism; Anesthesia; Animals; Anticholinergics; Bioavailability; Cholinergic Antagonists - pharmacokinetics; Clinical decision making; Cognitive ability; Cytochrome; Cytochrome P-450 Enzyme System - genetics; Delirium; Dementia; Drugs; Enzymes; Exocrine glands; Female; Females; Human subjects; Humans; Male; Metabolism; Metabolites; Older people; Pharmacokinetics; Pharmacology; Polymorphism, Genetic; Proteins; Receptors, Muscarinic - metabolism; Review; Reviews; Sex Characteristics; sex differences; Smooth muscle; Women; pharmacokinetics; aging; anticholinergics; sex differences

There is evidence that use of drugs with anticholinergic properties increases the risk of cognitive impairment, and increased exposure to these drugs potentiates this risk. Anticholinergic drugs are commonly used even with associated risk of adverse events. Aging, sex, and genetic polymorphisms of c...